Impact of A. Lumbricoides on Pulmonary Aspergillosis Development

Launched by RESEARCH INSTITUTE OF EPIDEMIOLOGY, MICROBIOLOGY AND INFECTIOUS DISEASES, UZBEKISTAN · Mar 23, 2023

Keywords

ClinConnect Summary

This clinical trial is looking into how a type of roundworm called Ascaris lumbricoides might affect the development of a lung infection known as pulmonary aspergillosis in patients with chronic obstructive pulmonary disease (COPD). Researchers want to find out how common this worm infection is in COPD patients—whether they have pulmonary aspergillosis, have the worm infection, or both—compared to healthy individuals. They will also study certain substances in the body called cytokines that could help understand how these infections interact.

To participate in this study, you need to be a COPD patient, which means you have a chronic lung condition that makes it hard to breathe. You can join if you have a lung infection (aspergillosis), a worm infection (ascariasis), or both. Healthy individuals without these conditions are also welcome to join as a comparison group. Unfortunately, if you have other autoimmune diseases, cancer, or different infections, you won’t be able to participate. If you join, you can expect to provide some health information and possibly undergo tests related to these conditions, helping researchers learn more about the links between these infections and COPD.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • COPD patients
• • COPD patients with aspergillosis
• • COPD patients with ascariasis
• • COPD patients with mix-infection
• • Healthy individuals (controls)
• Exclusion Criteria:
• • COPD patients with other autoimmune diseases
• • COPD patients with oncological diseases
• • COPD patients with other co-infections